It is presumed that this is due to the rapid decrease in HbA1c during the first 16 weeks of treatment
If a drug has not been approved by FDA, it is generally unlawful to market it, regardless of who prescribes it, how it is branded, or what disclaimer appears on the packaging
Semaglutide typically starts at 0.25 mg weekly, increasing to 0.5 mg, then 1.0 mg, and potentially up to 2.4 mg depending on response and tolerance
Lastly, as previously mentioned, reverse causality should be suspected when PDAC cases are reported after a short duration of exposure, which is not biologically plausible
It's currently seeking regulatory approval to issue Ozempic in packs of tablets
So what was Cubans response at last weeks Forbes Healthcare Summit